| 價(jià)格 | 詢價(jià) | ||
| 包裝 | 100ug | 500ug | 1000ug |
| 最小起訂量 | 100ug |
| 發(fā)貨地 | 北京 |
| 更新日期 | 2026-06-30 |
| 中文名稱:TPO R蛋白 | 英文名稱:Thrombopoietin R |
| 品牌: 百普賽斯 | 產(chǎn)地: 北京 |
| 保存條件: -20°C to -70°C | 純度規(guī)格: 99% |
| 產(chǎn)品類別: 重組蛋白 | |
| 貨號(hào): THR-H52H7 | 用途范圍: 生物研發(fā) |
| 規(guī)格: 100ug | 是否進(jìn)口: 否 |
| 靶點(diǎn): TPO R | 種屬: 人 |
| 表達(dá)系統(tǒng): HEK293 | 標(biāo)簽: His Tag |
分子別名(Synonym)
MPL, C-MPL, CD110, MPLV, THCYT2, TPOR
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human Thrombopoietin R, His Tag (THR-H52H7) is expressed from human 293 cells (HEK293). It contains AA Gln 26 - Trp 491 (Accession # P40238-1).
Predicted N-terminus: Gln 26
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 54.4 kDa. The protein migrates as 60-66 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method / rFC method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

背景介紹
血小板生成素受體(簡(jiǎn)稱TPO-R)主要表達(dá)于巨核細(xì)胞、血小板、成血細(xì)胞和造血干細(xì)胞表面。當(dāng)TPO與巨核細(xì)胞表面的TPO-R結(jié)合時(shí),可產(chǎn)生多重生物學(xué)效應(yīng):防止巨核細(xì)胞凋亡;提升巨核細(xì)胞數(shù)量、增大細(xì)胞體積及增加核內(nèi)倍體數(shù);加速巨核細(xì)胞成熟進(jìn)程;并介導(dǎo)TPO/TPO-R復(fù)合物的內(nèi)化。該受體參與JAK、STAT、MAP激酶等多種信號(hào)轉(zhuǎn)導(dǎo)通路。
| 成立日期 | 2010-07-22 (17年) | 注冊(cè)資本 | 8000萬(wàn)人民幣 |
| 員工人數(shù) | 500人以上 | 年?duì)I業(yè)額 | ¥ 1億以上 |
| 主營(yíng)行業(yè) | 醫(yī)藥中間體,原料藥,激素類,氨基糖苷類,中樞神經(jīng)系統(tǒng)用藥 | 經(jīng)營(yíng)模式 | 工廠,試劑 |
| 產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| 詢價(jià) |
VIP4年
|
武漢佰樂(lè)博生物技術(shù)有限公司
|
2026-07-29 | |
| ¥2660 |
VIP5年
|
上海博爾森生物科技有限公司
|
2026-07-29 | |
| ¥2460 |
VIP7年
|
上海澤葉生物科技有限公司
|
2026-07-29 |